New combo therapy aims to shrink stomach cancer spread

This study tests a treatment plan for people with stomach cancer that has spread to the lining of the abdomen. The plan combines heated chemotherapy directly in the abdomen (HIPEC), standard chemotherapy, and an immunotherapy drug called tislelizumab. The goal is to see if this combination can shrink the cancer enough to allow for complete surgical removal. About 30 adults who have not had prior treatment will take part.